TABLE 2

Vaccine Coverage at 5 Months

Vaccine11- to 12-Year-Olds (n = 32 676)13- to 18-Year-Olds (n = 74 767)
Coverage at 5 mo (%)Coverage Change Over Previous 5 mo (%)Difference From ControlPCoverage at 5 mo (%)Coverage Change Over Previous 5 mo (%)Difference From Control P
%95% CI%95% CI
Tdap
 Control84.94.2Ref79.13.4Ref
 In-person90.47.63.42.2 to 4.6<.00180.73.50.1–0.9 to 1.0.88
 Webinar92.57.83.62.4 to 4.9<.00180.23.1−0.4–1.3 to 0.5.41
Meningococcal
 Control53.87.6Ref71.54.0Ref
 In-person62.112.44.72.3 to 7.2<.00172.44.70.7–0.5 to 2.0.25
 Webinar59.612.04.42.0 to 6.8<.00165.94.80.8–0.5 to 2.1.21
HPV (≥1 dose)a
 Control32.33.5Ref59.83.5Refa
 In-person29.04.91.50.3 to 2.7.0261.53.90.4–0.7 to 1.5.49
 Webinar31.15.31.90.7 to 3.1<.0157.73.4−0.1–1.2 to 0.9.81
HPV (3 doses)a
 Control11.01.8Ref35.21.9Ref
 In-person11.31.90.1–0.5 to 0.7.6540.92.60.70.1 to 1.3.03
 Webinar11.02.00.2–0.3 to 0.8.4238.52.40.5–0.1 to 1.1.10
MMR (2 doses)
 Control82.30.0Ref79.30.1Ref
 In-person81.90.00.0b77.00.10.0b
 Webinar86.30.10.0b80.30.10.0b
HBV (3 doses)
 Control87.20.0Ref82.80.1Ref
 In-person85.60.00.0b79.90.10.0b
 Webinar89.70.10.0b81.80.10.0b
Varicella (2 doses)
 Control67.41.2Ref51.11.1Ref
 In-person67.01.80.5–0.1 to 1.1.0952.61.20.1–0.3 to 0.6.61
 Webinar71.43.01.80.8 to 2.8<.0155.61.50.4–0.1 to 0.9.10
  • Intervention arms had different coverage changes only for varicella vaccination among 11- to 12-year-olds (1.2% [95% CI: 0.2 to 2.3]).

  • Vaccine coverage is unadjusted. Vaccine coverage change and difference from control are adjusted for publicly funded vaccine doses and account for clustering by clinic. Dashes (–) indicate empty cells related to reference categories or suppressed data.

  • a HPV coverage assessed only for female 11- to 12-year-old patients (n = 14 994) and 13- to 18-year-old patients (n = 35 375).

  • b CIs and P values for difference estimates suppressed due to small cell sizes.